Table 1.
Summary table describing the properties of anti-BCMA immunotoxin variants.
| Immunotoxin | Description | Molecular Weight (kDa) | IC50 in H929 (ng/mL) | In Vivo Efficacy (H929 SC Xenograft) | In Vivo Efficacy (H929 BM Xenograft) | Reference |
|---|---|---|---|---|---|---|
| LMB 70 | BM306-Fab-LRggs | 72 | 1.1 | Growth Inhibition | Complete Response | [35] |
| LMB 107 | BM306-dsFv-PE38 | 62 | 1.1 | Growth Inhibition | ND | [38] |
| LMB 75 | BM306-dsFv-LRggs | 48 | 1.3 | Growth Inhibition | Complete Response | [41] |
| LMB 162 | BM306-dsFv-ABD-LRggs | 54 | 3.6 | Growth Inhibition | ND | [38] |
| LMB 173 | BM306-dsFv-MSA21-LRggs | 58 | 2.4 | ND | ND | [38] |
| LMB 92 | BM306-Fab-LO10R456A | 72 | 3.1 | Growth Inhibition | ND | [38] |
| LMB 103 | BM306-Fab-T20 | 72 | 6.0 | ND | ND | [38] |
| LMB 267 | BM306-Fab-T20 A494R | 72 | 1.1 | ND | Complete Response | [38] |
ND: Not done; SC: Subcutaneous; BM: Bone marrow.